Literature DB >> 8018563

Developmental expression of the RET protooncogene.

V Avantaggiato1, N A Dathan, M Grieco, N Fabien, D Lazzaro, A Fusco, A Simeone, M Santoro.   

Abstract

The RET protooncogene encodes a transmembrane protein of the receptor-type tyrosine kinase family whose ligand has not yet been identified. Its activation in vivo is restricted to human carcinomas of the thyroid. In order to learn more about the possible role played by RET during normal development, we have examined its expression by performing in situ hybridization experiments on mouse embryos. Here, we show that the RET protooncogene is expressed during mouse embryogenesis in an unusual temporal and spatial manner. In fact, its expression was first detected around day 10 of gestation in the basal plate of the neural tube and in the developing encephalic ganglia, and later its pattern of expression was definitely established in neural structures, mostly in neural crest derivatives (spinal and encephalic ganglia). As far as the central nervous system is concerned, RET expression was confined to the ventral part of the midbrain from 12.5 days postcoitum (dpc) until birth. RET was also found to be expressed within structures of sensory organs such as the ganglial layer of the retina and the olfactory epithelium. A peculiar pattern of RET expression was clearly observed in the wall of the gut and in the nephrogenic zone of the developing kidney cortex, specifically in the metanephrogenic vesicles. Finally, RET was found to be expressed in the liver mostly between 12.5 dpc and 14.5 dpc. In conclusion, its expression in the early stages of embryogenesis suggests that RET may play a role in the differentiation of specific neural structures and the excretory system.

Entities:  

Mesh:

Year:  1994        PMID: 8018563

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  29 in total

1.  Mutation of RET proto-oncogene in Hirschsprung's disease and intestinal neuronal dysplasia.

Authors:  Jin-Fa Tou; Min-Ju Li; Tao Guan; Ji-Cheng Li; Xiong-Kai Zhu; Zhi-Gang Feng
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

2.  Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.

Authors:  M P Cosma; M Cardone; F Carlomagno; V Colantuoni
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 3.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

Review 4.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

5.  Investigation of germline GFR alpha-1 mutations in Hirschsprung disease.

Authors:  S M Myers; R Salomon; A Goessling; A Pelet; C Eng; A von Deimling; S Lyonnet; L M Mulligan
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

6.  Studies of RET gene expression and acetylcholinesterase activity in a series of sporadic Hirschsprung's disease.

Authors:  Maria Cecília M Coelho; Uenis Tannuri; Israel Benditt; Maria Merces Santos
Journal:  Pediatr Surg Int       Date:  2008-07-30       Impact factor: 1.827

7.  Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons.

Authors:  K Krieglstein; P Henheik; L Farkas; J Jaszai; D Galter; K Krohn; K Unsicker
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

8.  Induction of RET dependent and independent pro-inflammatory programs in human peripheral blood mononuclear cells from Hirschsprung patients.

Authors:  Marta Rusmini; Paola Griseri; Francesca Lantieri; Ivana Matera; Kelly L Hudspeth; Alessandra Roberto; Joanna Mikulak; Stefano Avanzini; Valentina Rossi; Girolamo Mattioli; Vincenzo Jasonni; Roberto Ravazzolo; William J Pavan; Alessio Pini-Prato; Isabella Ceccherini; Domenico Mavilio
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

9.  Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis.

Authors:  Q C Vega; C A Worby; M S Lechner; J E Dixon; G R Dressler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 10.  On the Origin of Cells and Derivation of Thyroid Cancer: C Cell Story Revisited.

Authors:  Mikael Nilsson; Dillwyn Williams
Journal:  Eur Thyroid J       Date:  2016-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.